| Literature DB >> 31210421 |
Weipeng Zhan1,2,3, Ming Hu1,2,3, Caiwen Han1,2,4, Hongwei Tian1,2,3, Wutang Jing1,2,3, Xiaofei Li1,2, Hao Shi1,2, Xiaojun Yang1,2,3, Tiankang Guo1,2,3,4, He Su1,2,3, Yuntao Ma1,2,3.
Abstract
BACKGROUND: Recently, no relevant research has focused on the relationship between the clinical efficacy of da Vinci robotic distal pancreatectomy (RDP) and the number of mechanical arms and assistants used for RDP. The aim of this study was to evaluate the safety, efficacy, and advantages of RDP with the "3 + 2" mode.Entities:
Keywords: distal pancreatectomy; pancreatic neoplasm; robotic surgical; “3+2” mode
Mesh:
Year: 2019 PMID: 31210421 PMCID: PMC6675730 DOI: 10.1002/cam4.2353
Source DB: PubMed Journal: Cancer Med ISSN: 2045-7634 Impact factor: 4.452
Figure 1(A) R1, Robotic first arm; R2, robotic second arm; A1, the first assistant; A2, the second assistant; C, the camera arm. (B) R1, Robotic first arm; R2, robotic second arm; R3, robotic third arm; A1, the first assistant; C, the camera arm
Characteristics of patient between the two techniques
| Patients characteristics | Observation group (n = 53) | Control group (n = 53) |
|
|---|---|---|---|
| Gender (M/F) | 35/18 | 29/24 | 0.233 |
| Age, median (IQR), y | 42 (38‐50) | 39 (35‐45) | 0.081 |
| BMI, mean (SD), kg/m2 | 24.3 ± 2.0 | 23.7 ± 1.9 | 0.112 |
| Largest tumor size, mean (SD), mm | 34.3 ± 9.3 | 32.1 ± 6.6 | 0.147 |
| Malignancy, n (%) | 17 (32.1) | 21 (39.6) | 0.418 |
| I | 2 (3.8) | 6 (11.3) | |
| II | 11 (20.8) | 14 (26.4) | |
| III | 4 (7.5) | 1 (1.9) | |
| ASA score, n (%) | |||
| 1 | 9 (17) | 3 (5.7) | 0.158 |
| 2 | 41 (77.4) | 45 (84.9) | |
| 3 | 3 (5.7) | 5 (9.4) | |
Values are presented as mean (SD) or n (%); median (25th, 75th percentile) as IQR.
Chi‐squared test.
Mann‐Whitney test.
t test.
Surgical outcomes, and short‐term postoperative course and cost analysis
| Clinical parameters | Observation group (n = 53) | Control group (n = 53) |
|
|---|---|---|---|
| Operative time, mean (SD), min | 166.9 ± 13.3 | 192.6 ± 11.1 | <0.001 |
| Estimated blood loss, median (IQR), mL | 90 (70‐155) | 110 (80‐175) | 0.275 |
| Conversion to open procedure, n (%) | 0 (0) | 2 (3.8) | 0.495 |
| Blood transfusion, n (%) | 1 (3.3) | 0 (0) | 0.315 |
| Postoperative hospital stay, median (IQR), d | 12 (10‐14) | 11 (9.5‐13) | 0.261 |
| Time to passage of flatus, mean (SD), d | 2.5 ± 0.6 | 2.3 ± 0.5 | 0.089 |
| Postoperative complications, n (%) | 12 (22.6) | 15 (28.3) | 0.328 |
| Clavien 1‐2, n (%) | 8 (15.1) | 13 (24.5) | 0.165 |
| Clavien ≥3, n (%) | 4 (7.5) | 2 (3.8) | 0.339 |
| Pancreatic leakage (%) | 2 (3.8) | 3 (5.7) | 0.647 |
| Chylous leakage (%) | 2 (3.8) | 1 (1.9) | 0.558 |
| Bowel obstruction, n (%) | 0 (0) | 2 (3.8) | 0.248 |
| Wound infection (%) | 3 (5.7) | 2 (3.8) | 0.647 |
| Delayed gastric emptying (%) | 1 (1.9) | 1 (1.9) | 0.752 |
| Pulmonary infection (%) | 1 (1.9) | 4 (7.5) | 0.363 |
| Total hospitalization cost, mean (SD), $ | 9891.38 ± 675.5 | 11222.43 ± 904.24 | <0.001 |
| Operation cost, mean (SD), $ | 2827.79 ± 173.02 | 3900.63 ± 317.29 | <0.001 |
| 30‐day readmission | 5 (9.4) | 3 (5.7) | 0.462 |
| 90‐day mortality | 0 | 0 | — |
Values are presented as mean (SD) or n (%); median (25th, 75th percentile) as IQR.
Chi‐squared test.
Mann‐Whitney test.
t test.
Fisher's exact test.
Multivariable linear regression model of factors associated with OT, OC
| Factors | Operative time (OT) |
| Operation cost (OC) |
| ||
|---|---|---|---|---|---|---|
| Coeff | 95% CI | Coeff | 95% CI | |||
| Control group | 24.32 | 19.28 to 29.36 | <0.001 | 1089.42 | 941.28 to 1237.55 | <0.001 |
| Female | 2.05 | −2.83 to 6.94 | 0.407 | 0.22 | −0.3.62 to 104.05 | 0.997 |
| Age (y) | −0.08 | −0.37 to 0.22 | 0.606 | 1.12 | −5.21 to 7.41 | 0.729 |
| BMI (kg/m2) | −0.51 | −1.79 to 0.78 | 0.434 | −4.56 | −31.85 to 22.73 | 0.741 |
| Largest tumor size (cm) | −0.18 | −0.48 to 0.12 | 0.243 | −2.61 | −9.09 to 3.89 | 0.428 |
| Estimated blood loss (mL) | 0.02 | −0.08 to 0.04 | 0.199 | −0.08 | −0.59 to 0.42 | 0.743 |
| Postoperative hospital stay (d) | — | — | — | — | — | — |
| Time to passage of flatus (d) | — | — | — | — | — | — |
| Operative time (min) | — | — | — | −0.84 | −5.06 to 3.39 | 0.695 |
Abbreviations: Coeff, coefficient; CI, confidence interval; BMI, body mass index.
In reference to Observation group.
In reference to males.
Preservation of the spleen and spleen vessels between the two groups
| Clinical parameters | Observation group (n = 53) | Control group (n = 53) |
|
|---|---|---|---|
| Spleen preservation, n (%) | 27 (50.9) | 23 (43.4) | 0.436 |
| Spleen preservation excluded malignancy, n (%) | 27 (75.0) | 23 (71.9) | 0.493 |
| Spleen vessels preservation, n (%) | 15 (28.3) | 10 (18.9) | 0.253 |
| Spleen vessels preservation excluded malignancy, n (%) | 15 (41.7) | 10 (31.3) | 0.374 |
Data are shown as n (%). Chi‐squared test was used for between‐group comparison.
Fisher's exact test.
Clinicopathologic characteristics of patients between the two groups
| Histopathology, n (%) | Observation group (n = 53) | Control group (n = 53) |
|
|---|---|---|---|
| Neuroendocrine tumor, n (%) | 9 (16.9) | 2 (3.8) | 0.833 |
| Mucinous cystadenoma, n (%) | 13 (24.5) | 15 (28.3) | 0.659 |
| Serous cystadenoma, n (%) | 6 (11.3) | 2 (3.8) | 0.135 |
| Solid pseudopapillary neoplasm, n (%) | 1 (1.9) | 6 (11.3) | 0.056 |
| Intraductal papillary mucinous neoplasm, n (%) | 5 (9.4) | 7 (13.2) | 0.382 |
| Acinar cells neoplasm, n (%) | 0 (0) | 1 (1.9) | 0.500 |
| Pancreatic ductal adenocarcinoma, n (%) | 16 (30.2) | 14 (26.4) | 0.666 |
| Others, n (%) | 3 (5.7) | 6 (11.3) | 0.244 |
Data are shown as n (%). Chi‐squared test was used for between‐group comparison.
Fisher's exact test.